文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

Tanezumab对髋或膝骨关节炎关节疼痛、身体功能和患者整体评估的影响:一项随机临床试验

Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01

这项随机双盲多中心试验纳入698例对镇痛药反应不足的髋或膝骨关节炎患者,比较皮下注射Tanezumab 2.5 mg、2.5/5 mg与安慰剂。16周时,两个Tanezumab组在WOMAC疼痛、身体功能和PGA-OA评分上均较安慰剂有统计学显著改善,但改善幅度 modest,且Tanezumab组关节安全事件和全关节置换更多。

要点

  • Tanezumab 2.5 mg和2.5/5 mg在16周时显著改善WOMAC疼痛、功能及PGA-OA评分。
  • 改善幅度较小,需权衡临床意义。
  • Tanezumab组快速进展性OA和全关节置换发生率高于安慰剂组。

核心结论

  • 在对标准镇痛药反应不足的中重度髋或膝骨关节炎患者中,Tanezumab较安慰剂显著改善疼痛、身体功能和患者整体评估,但改善幅度 modest,且关节安全事件和全关节置换更多。

研究设计与样本

  • 随机、双盲、多中心试验,2016年1月至2018年5月14日(末次患者访视)进行。
  • 纳入698例18岁及以上髋或膝骨关节炎患者,对OA镇痛药反应不足,无预设关节安全条件的影像学证据。
  • 患者随机接受皮下注射Tanezumab 2.5 mg(第1天和第8周,n=231)、Tanezumab 2.5 mg(第1天)和5 mg(第8周)(即2.5/5 mg,n=233)或安慰剂(第1天和第8周,n=232)。
  • 696例接受至少1次治疗剂量(平均[SD]年龄60.8[9.6]岁;65.1%女性),582例(83.6%)完成试验。

主要发现

  • 快速进展性OA仅发生于Tanezumab治疗患者(2.5 mg组n=5,2.2%;2.5/5 mg组n=1,0.4%)。
  • 全关节置换发生率在Tanezumab 2.5 mg组为8例(3.5%),2.5/5 mg组为16例(6.9%),安慰剂组为4例(1.7%)。

临床怎么用

  • 对于对标准镇痛药反应不足的中重度髋或膝骨关节炎患者,Tanezumab可带来统计学显著的疼痛和功能改善,但幅度较小。
  • 使用Tanezumab需警惕快速进展性OA和全关节置换风险增加,应个体化评估获益与风险。

局限性

  • 疗效改善幅度 modest,临床重要性需进一步研究确定。
  • 关节安全事件和全关节置换增加,需长期安全性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with osteoarthritis (OA) may remain symptomatic with traditional OA treatments. OBJECTIVE: To assess 2 subcutaneous tanezumab dosing regimens for OA. DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, multicenter trial from January 2016 to May 14, 2018 (last patient visit). Patients enrolled were 18 years or older with hip or knee OA, inadequate response to OA analgesics, and no radiographic evidence of prespecified joint safety conditions. INTERVENTIONS: Patients received by subcutaneous administration either tanezumab, 2.5 mg, at day 1 and week 8 (n = 231); tanezumab, 2.5 mg at day 1 and 5 mg at week 8 (ie, tanezumab, 2.5/5 mg; n = 233); or placebo at day 1 and week 8 (n = 232). MAIN OUTCOMES AND MEASURES: Co-primary end points were change from baseline to week 16 in Western Ontario and McMasters Universities Osteoarthritis Index (WOMAC) Pain (0-10, no to extreme pain), WOMAC Physical Function (0-10, no to extreme difficulty), and patient global assessment of osteoarthritis (PGA-OA) (1-5, very good to very poor) scores. RESULTS: Among 698 patients randomized, 696 received 1 or more treatment doses (mean [SD] age, 60.8 [9.6] years; 65.1% women), and 582 (83.6%) completed the trial. From baseline to 16 weeks, mean WOMAC Pain scores decreased from 7.1 to 3.6 in the tanezumab, 2.5 mg, group; 7.3 to 3.6 in the tanezumab, 2.5/5 mg, group; and 7.3 to 4.4 in the placebo group (least squares mean differences [95% CI] vs placebo were -0.60 [-1.07 to -0.13; P = .01] for tanezumab, 2.5 mg, and -0.73 [-1.20 to -0.26; P = .002] for tanezumab, 2.5/5 mg). Mean WOMAC Physical Function scores decreased from 7.2 to 3.7 in the 2.5-mg group, 7.4 to 3.6 in the 2.5/5-mg group, and 7.4 to 4.5 with placebo (differences vs placebo, -0.66 [-1.14 to -0.19; P = .007] for tanezumab, 2.5 mg, and -0.89 [-1.37 to -0.42; P < .001] for tanezumab, 2.5/5 mg). Mean PGA-OA scores decreased from 3.4 to 2.4 in the 2.5-mg group, 3.5 to 2.4 in the 2.5/5-mg group, and 3.5 to 2.7 with placebo (differences vs placebo, -0.22 [-0.39 to -0.05; P = .01] for tanezumab, 2.5 mg, and -0.25 [-0.41 to -0.08; P = .004] for tanezumab, 2.5/5 mg). Rapidly progressive OA occurred only in tanezumab-treated patients (2.5 mg: n = 5, 2.2%; 2.5/5 mg: n = 1, 0.4%). The incidence of total joint replacements was 8 (3.5%), 16 (6.9%), and 4 (1.7%) in the tanezumab, 2.5 mg; tanezumab, 2.5/5 mg; and placebo groups, respectively. CONCLUSIONS AND RELEVANCE: Among patients with moderate to severe OA of the knee or hip and inadequate response to standard analgesics, tanezumab, compared with placebo, resulted in statistically significant improvements in scores assessing pain and physical function, and in PGA-OA, although the improvements were modest and tanezumab-treated patients had more joint safety events and total joint replacements. Further research is needed to determine the clinical importance of these efficacy and adverse event findings. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02697773.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Schnitzer TJ, Easton R, Pang S, et al. Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial. JAMA. 2019. PMID: 31265100. doi:10.1001/jama.2019.8044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。